DESIRAE TWILLA: Open Payments
NPI 1437554318 · MURFREESBORO, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$496 in 22 payments from 12 companies in 2025. Trend: 2023 $1,061 · 2024 $839 · 2025 $496
Food & beverage: $496
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $138 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| ABBVIE INC. | 3 | $64 |
| Novo Nordisk Inc | 3 | $63 |
| Astellas Pharma US Inc | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: CAPLYTA, REXULTI, VRAYLAR, Ozempic, Veozah, GEMTESA, NEXLETOL, JOURNAVX.
Industry payments across TN — which companies pay providers there.
